Clinical Trial Update: S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Erlotinib for advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Lung
• Large Cell Lung Cancer
• Non-small Cell Lung Cancer
• Squamous Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Lung, Large Cell Lung Cancer | Phase 2 | Status: COMPLETED